Features | Partner Sites | Information | LinkXpress
Sign In
Fluke Biomedical
Schiller
GLOBETECH PUBLISHING

Microsensor Measures Intraocular Pressure in Glaucoma

By HospiMedica International staff writers
Posted on 19 Aug 2014
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
An implantable microsensor for wireless intraocular pressure (IOP) measurement allows close monitoring of patients’ disease status and glaucoma therapy success.

The Pro-IOP eye pressure measurement system consists of an implantable microsensor, an external hand held device that telemetrically transfers energy to the microsensor, and a cellular GSM module, which connects with the hand held device to transfer measurement data to a database that can be accessed by clinicians to review the disease status of the patient. Optionally, the patient can also have limited access to the data via an App, in order to review data history or communicate with the ophthalmologist.

The Pro-IOP delivers direct and real IOP, as expressed in mm Hg, which facilitates measurement without disrupting the patient’s lifestyle and without compromising the patient’s behavior. At the same time, the system discloses to clinicians real time, crucial information regarding patient specific pressure fluctuation and variability, shows if the chosen therapeutic measures work, and reports patient therapy adherence. The system is designed for easy patient use and can also be integrated into telemedicine systems for remote patient management.

The Pro-IOP eye pressure measurement system is a product of Implandata Ophthalmic Products (Hannover, Germany). The company has recently reported the successful implantation of the first patient within the ARGOS-02 clinical study, held at Augenklinik Bellevue (Kiel, Germany). In the ARGOS-02 clinical study, six eye centers in Germany are currently recruiting primary open angle glaucoma patients undergoing cataract extraction.

“So far the first results of this innovative product are very compelling,” said Prof. Detlef Uthoff, MD, medical director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient.”

Related Links:

Implandata Ophthalmic Products
Augenklinik Bellevue



ACEM
ECR
Cincinnati Sub-Zero

Channels

Surgical Techniques

view channel
Image

Transport System Extends Utilization of Robotic Surgery

A new transport system will allow the Magellan robotic system to be a shared hospital resource, giving multiple physician specialties access in several settings. The Magellan Transport System, which... Read more

Women's Health

view channel

Aspirin Reduces Breast Cancer Recurrence in Overweight Women

The recurrence of hormone-related breast cancer was reduced by more than half in overweight and obese women who regularly used nonsteroidal anti-inflammatory drugs (NSAIDs), according to a new study. Researchers at the University of Texas (UT; Austin, USA) conducted a retrospective review of data from 440 women with... Read more

Business

view channel

Lloyds Bank Establishes Specialist Healthcare Teams

As part of a substantial restructure, Lloyds Bank Commercial Banking (London, United Kingdom) has launched two specialist healthcare relationship teams. Designated part of the small and medium enterprise (SME) commercial banking division, the two teams will offer industry-specific support for firms in London (United Kingdom).... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.